Humoral response after BNT162b2 vaccination in hemodialysis patients

Humoral response after BNT162b2 vaccination in Japanese hemodialysis patients - Effectiveness of BNT162b2 vaccine in Japanese hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047032

Enrollment

294

Registered

2022-03-01

Start date

2021-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure during hemodialysis

Interventions

One hundred and eighty-five hemodialysis patients were vaccinated with 30 mg of BNT162b2 vaccine twice at 3-week intervals. Two weeks later, SARS-CoV-2 IgG antibodies were measured. Patients were also

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing hemodialysis three times a week at our hospital

Exclusion criteria

Exclusion criteria: Patients who have had COVID-19 in the past

Design outcomes

Primary

Measure	Time frame
Antibody acquisition rate by BNT162b2 vaccine	—

Secondary

Measure	Time frame
Adverse events caused by BNT162b2 vaccine	—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp0776211277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026